Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-24, Stock:ABBV, The news for the past five days is as follows:
2018-08-17: NEWS1: 3 Growth Stocks for Successful Investors.NEWS2: 3 Growth Stocks for Successful Investors.NEWS3: 3 Growth Stocks for Successful Investors.NEWS4: New Drugs Approved In July.NEWS5: New Drugs Approved In July.
2018-08-20: NEWS1: AbbVie donates $100M to Ronald McDonald House Charities.NEWS2: 8 Undervalued Biotech Stocks to Watch.NEWS3: 8 Undervalued Biotech Stocks to Watch.NEWS4: Bay Area&apos;s 10th life science IPO this year raises $26M as No. 11 hopes to fetch $86M.NEWS5: Ronald McDonald House Houston receives its largest gift, part of $100M from AbbVie.NEWS6: Allergan’s International Business Segment in Q2 2018.NEWS7: 8 Undervalued Biotech Stocks to Watch.NEWS8: Allergan’s US Specialized Therapeutics Segment in Q2 2018.
2018-08-21: NEWS1: SHAREHOLDER ALERT: GLNCY GLCNF COOL FIZZ SBGL GOGO ACAD ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS2: Trade of the Day: AbbVie (ABBV).NEWS3: Trade of the Day: AbbVie (ABBV).NEWS4: 5 Low-Cost Biotech Stocks With High Levels of Growth.NEWS5: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline - September 24, 2018.NEWS6: Trade of the Day: AbbVie (ABBV).
2018-08-22: NEWS1: 3 Undervalued Dividend Stocks to Buy.NEWS2: 3 Undervalued Dividend Stocks to Buy.NEWS3: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS4: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS5: Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX.NEWS6: Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX.NEWS7: AbbVie Is Focused on Diversifying Its Portfolio in 2018.NEWS8: Oncology Is a Major Growth Driver for AbbVie in 2018.NEWS9: European shares steady as trade talks, U.S. politics fuel uncertainty.NEWS10: AbbVie Has Raised Its EPS Guidance for 2018.NEWS11: Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug.NEWS12: AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids.NEWS13: AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix.NEWS14: AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix.NEWS15: AbbVie doubles down on cancer project with biotech group Argenx.
2018-08-23: NEWS1: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, FPI, FIZZ, ACAD, TTPH and ABBV.NEWS2: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS3: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS4: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS5: Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone.NEWS6: Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone.

Answer: Rise